These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9094480)

  • 21. Cardiovascular considerations in using topical, oral, and intravenous drugs for the treatment of glaucoma and ocular hypertension: focus on beta-adrenergic blockade.
    Frishman WH; Kowalski M; Nagnur S; Warshafsky S; Sica D
    Heart Dis; 2001; 3(6):386-97. PubMed ID: 11975823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allergic contact dermatitis due to the beta-blocker carteolol in eyedrops.
    Sánchez-Pérez J; Córdoba S; Bartolomé B; García-Díez A
    Contact Dermatitis; 1999 Nov; 41(5):298. PubMed ID: 10554073
    [No Abstract]   [Full Text] [Related]  

  • 23. Systemic effects of topical beta-blocker therapy: the family physician's role.
    White GL; Crandall AS; Harrow J; Goodenough G
    J Fam Pract; 1991 Jan; 32(1):99-101. PubMed ID: 1670641
    [No Abstract]   [Full Text] [Related]  

  • 24. Current use of ophthalmic beta blockers.
    Gross RL; Pineyro A
    J Glaucoma; 1997 Jun; 6(3):188-91. PubMed ID: 9211143
    [No Abstract]   [Full Text] [Related]  

  • 25. [Structural and immunohistochemical changes of conjunctiva induced by topical glaucoma medication].
    Nenciu A; Stefan C; Ardelean C
    Oftalmologia; 2004; 48(1):35-42. PubMed ID: 15279417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Topical beta-blockers in patients with co-existing conditions: is this a cause for concern?
    Good CB
    Pharmacoepidemiol Drug Saf; 2001; 10(6):509-10. PubMed ID: 11828832
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmacokinetic and pharmacodynamic differences between ocular and nasal instillation of carteolol on intraocular pressure and heart rate in Japanese men with high CYP2D6 activity.
    Ishii Y; Nakamura K; Matsuki S; Uemura N; Muraguchi R; Nakagawa M; Nakano S; Nakatsuka K
    J Clin Pharmacol; 2002 Sep; 42(9):1020-6. PubMed ID: 12211218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Contact allergy to beta blockaders in eye drops: cross allergy?].
    Giordano-Labadie F; Lepoittevin JP; Calix I; Bazex J
    Ann Dermatol Venereol; 1997; 124(4):322-4. PubMed ID: 9739938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiac and extracardiac side effects of eye drops.
    Jolobe OMP
    Am J Emerg Med; 2021 Aug; 46():731. PubMed ID: 33039238
    [No Abstract]   [Full Text] [Related]  

  • 30. Phase III long-term study and comparative clinical study of nipradilol ophthalmic solution in patients with primary open-angle glaucoma and ocular hypertension. Part 2.
    Kanno M; Araie M; Masuda K; Takase M; Kitazawa Y; Shiose Y; Azuma I; Ogawa N; Ohdo S
    Arzneimittelforschung; 2006; 56(12):820-5. PubMed ID: 17260669
    [No Abstract]   [Full Text] [Related]  

  • 31. Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma.
    Schenker H; Maloney S; Liss C; Gormley G; Hartenbaum D
    Clin Ther; 1999 Jan; 21(1):138-47. PubMed ID: 10090431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resting pulse rates in a glaucoma clinic: the effect of topical and systemic beta-blocker usage.
    Tattersall C; Vernon S; Singh R
    Eye (Lond); 2006 Feb; 20(2):221-5. PubMed ID: 15803169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allergic contact dermatitis due to carteolol, with good tolerance to betaxolol.
    Gonzalo-Garijo MA; Zambonino MA; Pérez-Calderón R; Pérez-Rangel I; Sánchez-Vega S
    Dermatitis; 2011; 22(4):232-3. PubMed ID: 21781644
    [No Abstract]   [Full Text] [Related]  

  • 34. Topical beta-blockers are not associated with an increased risk of treatment for depression.
    Kaiserman I; Kaiserman N; Elhayany A; Vinker S
    Ophthalmology; 2006 Jul; 113(7):1077-80. PubMed ID: 16815397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Conjunctival changes related to topical treatment and effectiveness of surgery in glaucoma].
    Stefan C; Nenciu A; Balas M; Neacşu A; Dachin L; Ardelean C
    Oftalmologia; 2003; 59(4):19-23. PubMed ID: 15083680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Beta-blockers in collyria and their secondary effects].
    Mihail S
    Oftalmologia; 1990; 34(2):81-4. PubMed ID: 1983167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relation between office intraocular pressure and 24-hour intraocular pressure in patients with primary open-angle glaucoma treated with a combination of topical antiglaucoma eye drops.
    Nakakura S; Nomura Y; Ataka S; Shiraki K
    J Glaucoma; 2007 Mar; 16(2):201-4. PubMed ID: 17473730
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The potential systemic effect of topically applied beta-blockers in glaucoma therapy.
    Taniguchi T; Kitazawa Y
    Curr Opin Ophthalmol; 1997 Apr; 8(2):55-8. PubMed ID: 10168358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Depression and topical ophthalmic beta adrenergic blockade.
    Bourgeois JA
    J Am Optom Assoc; 1991 May; 62(5):403-6. PubMed ID: 1687576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study].
    Trinquand C; Romanet JP; Nordmann JP; Allaire C;
    J Fr Ophtalmol; 2003 Feb; 26(2):131-6. PubMed ID: 12660585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.